ladostigil ladostigil ladostigil (tv-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like alzheimer's disease, lewy body disease, and parkinson's disease. it acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase b inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. in addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like gdnf and bdnf, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well. ladostigilclinical dataother names-n-propylcarbamateroutes ofadministrationoralatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name -n-propylcarbamate cas number209394-27-4pubchem cid208907chemspider181005uniisw3h1usr4qkeggd03239chemical and physical dataformulac16h20n2o2molar mass272.348 g·mol−1